Dr. Weiss on Developments in the Treatment of Head and Neck Cancer

Jared Weiss, MD
Published: Wednesday, Aug 09, 2017



Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.

There is a trial of pembrolizumab (Keytruda) in combination with radiation, which might one day replace cisplatin, explains Weiss.

There is also a study investigating durvalumab (Imfinzi) with carboplatin and nab-paclitaxel (Abraxane) as induction chemotherapy prior to surgery for hard-to-cure patients, states Weiss.
 


Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.

There is a trial of pembrolizumab (Keytruda) in combination with radiation, which might one day replace cisplatin, explains Weiss.

There is also a study investigating durvalumab (Imfinzi) with carboplatin and nab-paclitaxel (Abraxane) as induction chemotherapy prior to surgery for hard-to-cure patients, states Weiss.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x